Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | WDR5 | P61964 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059547 | 0.87 | HTT (0.58) | HTTSMN1; SMN2WDR5MAPTKMT2A | |
| SCHEMBL10224066 | 0.87 | KMT2A (0.56) | HTTSMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL10224183 | 0.84 | RORC (0.57) | HTTSMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL18585560 | 0.83 | HTT (0.56) | HTTSMN1; SMN2WDR5MAPTKMT2A | |
| SCHEMBL28581602 | 0.81 | WDR5 (0.62) | HTTSMN1; SMN2WDR5MAPTKMT2A | |
| SCHEMBL25394799 | 0.80 | KMT2A (0.56) | HTTSMN1; SMN2WDR5MAPTKMT2A | |
| SCHEMBL8218036 | 0.80 | MAPT (0.55) | SMN1; SMN2MAPTKMT2AALDH1A1MEN1 | |
| SCHEMBL19148638 | 0.79 | MAPT (0.64) | HTTSMN1; SMN2WDR5MAPTKMT2A | |
| SCHEMBL29074265 | 0.78 | KMT2A (0.64) | HTTWDR5MAPTKMT2AALDH1A1 | |
| SCHEMBL16441779 | 0.78 | MEN1 (0.69) | HTTSMN1; SMN2MAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2009032749-A2 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183889-A1 | SALICYLANILIDE MODIFIED PEPTIDES FOR USE AS ORAL THERAPEUTICS | DNPEP, PTMS, NGLY1 | HTT 1204/4885SMN1; SMN2 1291/4885WDR5 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.